144 related articles for article (PubMed ID: 36959285)
1. The usefulness of immunohistochemistry for phosphohistone H3 as a prognostic factor in myxoid liposarcoma.
Takazawa A; Yoshimura Y; Okamoto M; Tanaka A; Kito M; Aoki K; Uehara T; Takahashi J; Kato H; Nakayama J
Sci Rep; 2023 Mar; 13(1):4733. PubMed ID: 36959285
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
3. Phosphohistone-H3 (PHH3) is prognostic relevant in Merkel cell carcinomas but Merkel cell polyomavirus is a more powerful prognostic factor than AJCC clinical stage, PHH3, Ki-67 or mitotic indices.
Iwasaki T; Matsushita M; Nonaka D; Kato M; Nagata K; Murakami I; Hayashi K
Pathol Int; 2015 Aug; 65(8):404-9. PubMed ID: 25982855
[TBL] [Abstract][Full Text] [Related]
4. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
5. Predicting short-term recurrence in pituitary adenomas: Phosphohistone-H3 (Ser 10) proves an effective biomarker.
Li C; Wei L; Li L; Wang J; Li R; Zhang Q; Zhou D
Clin Neuropathol; 2020; 39(2):70-79. PubMed ID: 31724532
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer.
Goltz D; Montani M; Braun M; Perner S; Wernert N; Jung K; Dietel M; Stephan C; Kristiansen G
Pathology; 2015 Dec; 47(7):629-36. PubMed ID: 26517642
[TBL] [Abstract][Full Text] [Related]
7. The value of Phosphohistone H3 as a cell proliferation marker in oral squamous cell carcinoma. A comparative study with Ki-67 and the mitotic activity index.
Tancredi-Cueto N; Vigil-Bastitta G; Bologna-Molina R; Beovide-Cortegoso V
Med Oral Patol Oral Cir Bucal; 2022 Sep; 27(5):e444-e451. PubMed ID: 35975799
[TBL] [Abstract][Full Text] [Related]
8. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
Medani H; Elshiekh M; Naresh KN
J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.
Duregon E; Bertero L; Pittaro A; Soffietti R; Rudà R; Trevisan M; Papotti M; Ventura L; Senetta R; Cassoni P
Oncotarget; 2016 Apr; 7(16):21190-8. PubMed ID: 27049832
[TBL] [Abstract][Full Text] [Related]
10. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.
Aune G; Stunes AK; Tingulstad S; Salvesen O; Syversen U; Torp SH
Int J Clin Exp Pathol; 2011 Jun; 4(5):444-53. PubMed ID: 21738816
[TBL] [Abstract][Full Text] [Related]
11. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.
Ramani P; Taylor S; Miller E; Sowa-Avugrah E; May MT
J Histochem Cytochem; 2015 Jun; 63(6):397-407. PubMed ID: 25711230
[TBL] [Abstract][Full Text] [Related]
12. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
Puripat N; Loharamtaweethong K
Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
[TBL] [Abstract][Full Text] [Related]
14. Phosphohistone-H3 Proliferation Index Is Superior to Mitotic Index and MIB-1 Expression as a Predictor of Recurrence in Human Meningiomas.
Winther TL; Arnli MB; Salvesen Ø; Torp SH
Am J Clin Pathol; 2016 Oct; 146(4):510-20. PubMed ID: 27686177
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for the recurrence of myxoid liposarcoma: 20 cases with up to 8 years follow-up.
Lemeur M; Mattei JC; Souteyrand P; Chagnaud C; Curvale G; Rochwerger A
Orthop Traumatol Surg Res; 2015 Feb; 101(1):103-7. PubMed ID: 25583234
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.
Antonescu CR; Tschernyavsky SJ; Decuseara R; Leung DH; Woodruff JM; Brennan MF; Bridge JA; Neff JR; Goldblum JR; Ladanyi M
Clin Cancer Res; 2001 Dec; 7(12):3977-87. PubMed ID: 11751490
[TBL] [Abstract][Full Text] [Related]
18. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
19. Anti-phosphohistone H3 as an independent prognostic factor in human esophageal squamous cell carcinoma.
Nakashima S; Shiozaki A; Ichikawa D; Komatsu S; Konishi H; Iitaka D; Kubota T; Fujiwara H; Okamoto K; Kishimoto M; Otsuji E
Anticancer Res; 2013 Feb; 33(2):461-7. PubMed ID: 23393337
[TBL] [Abstract][Full Text] [Related]
20. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
